Angiotech receives clearance for new sizes of Quill SRS PDO
Angiotech Pharmaceuticals Inc. has received 510(k) clearance from the FDA for sizes 3–0 and 4–0 of its Quill Self-Retaining System (SRS) Polydioxanone (PDO) product offerings, which are longer lasting absorbable suture typically used for deeper tissue closures. The company indicated that these smaller diameter sizes incorporate a new design for better holding strength and expand the number and scope of procedures that can be done with the Quill SRS product.
- Medtronic gets FDA clearance for OneTouch UltraLink Meter
- Opto Circuits receives FDA nod to sell vital signs monitoring devices in US
- Handheld biomedical device for pain management
- FDA approves Ivera’s Curos™ Port Protector
